Search

everythinglearnresearchcommunity

for

Search:↓

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.

CD44 variant changes start alopecia areata, but don't maintain it.

CD271 is crucial for maintaining healthy skin and preventing inflammation.

Targeting CD169+ skin macrophages may help treat psoriasis.

Blocking certain immune signals can reduce skin damage from radiation therapy.

The Fas/FasL pathway may play a role in alopecia areata.

CD27 and IL-35 can help diagnose alopecia areata linked to bacterial infections.

CD44 signaling can help heal wounds without scars.

Certain immune system genes are linked to a higher risk of psoriasis and psoriatic arthritis, while others may offer protection.

CD117 and platelet-derived growth factor receptor α may play a role in alopecia areata.

Scientists found a new type of skin cell that could help with skin repair and these cells work better with a certain protein.

TEDAR is crucial for skin cell differentiation and barrier formation.

No CD44 in alopecia areata, present in normal and androgenetic alopecia.

Belatacept may be a promising treatment for alopecia areata.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

CD201+ fascia progenitors are essential for wound healing and could be targeted for treating skin conditions.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

GPRC5D is linked to the formation of hair, nails, and certain tongue areas.

Double-stranded RNA helps regenerate hair follicles by increasing retinoic acid production and signaling.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Retinoic acid can either maintain stem cells or make them specialize, depending on the cell type.

Higher CD70 and CD27 gene expression in alopecia areata lesions predicts disease severity and activity.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

FCER1A and RGS1 may help diagnose and treat systemic lupus erythematosus.